Competition Commission halts probe after J&J's TB drug pricing drops 40% with patent non-enforcement in 134 countries.
Competition Commission halts probe into Johnson & Johnson's TB drug pricing, after 40% price drop. The commission investigated allegations of abuse of dominance against the company and its subsidiary Janssen Pharmaceutica in the trade of Bedaquiline. Following intervention, the companies agreed not to enforce the patent in 134 countries, including South Africa, allowing for the entry of generic suppliers.
July 05, 2024
3 Articles